Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1497-1503

  Liu, Lihua ^a   Meng, Jun ^a   Zhang, Cong ^a   Duan, Yuqing ^a   Zhao, Lianmei ^a   Wang, Shijie ^a   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor; Apoptosis; Cell cycle; Interleukin 27; Pancreatic carcinoma

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN RECEPTOR; PROTEIN P21; RETROVIRUS VECTOR; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MARKER GENE; MOUSE; NONHUMAN; P28 LINKED EBI3 GENE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE; CYTOKINES; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; RETROVIRIDAE; TRANSPLANTATION, ISOGENEIC;

EID: 84863297929     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1663     Document Type: Article

References (30)

1. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G and Anichini A: Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677-4685, 2007. (Pubitemid 47294773)
2. Liu L, Wang S, Shan B, Sang M, Liu S and Wang G: Advances in viral-vector systemic cytokine gene therapy against cancer. Vaccine 28: 3883-3887, 2010.
3. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, et al: IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of native CD4+ T cells. Immunity 6: 779-790, 2002. (Pubitemid 34786477)
4. Pflanz S, Hibbert L, Mattson R, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R and Kastelein RA: WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 172: 2225-2231, 2004. (Pubitemid 38182370)
5. + T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol 2010: 605483, 2010.
6. Liu L, Wang S, Shan B, Shao L, Sato A, Kawamura K, Li Q, Ma G and Tagawa M: IL-27-mediated activation of natural killer cells and inflammation produced antitumor effects for human esophageal carcinoma cells. Scand J Immunol 68: 22-29, 2008. (Pubitemid 351798398)
7. Shinozaki Y, Wang S, Miyazaki Y, Miyazaki K, Yamada H, Yoshikai Y, Hara H and Yoshida H: Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int J Cancer 124: 1372-1378, 2009.
8. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D and Airoldi I: Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 16: 4188-4197, 2010.
9. Hu P, Hu HD, Chen M, Peng ML, Tang L, Tang KF, Matsui M, Belladonna ML, Yoshimoto T, Zhang DZ, et al: Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol 46: 1654-1662, 2009.
10. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J and Yoshimoto T: Antiangiogenic and antitumor activities of IL-27. J Immunol 176: 7317-7324, 2006. (Pubitemid 43849032)
11. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C and Mizuguchi J: Antiproliferative activity of IL-27 on melanoma. J Immunol 180: 6527-6535, 2008.
12. Nagai H, Oniki S, Fujiwara S, Xu M, Mizoguchi I, Yoshimoto T and Nishigori C: Antitumor activities of interleukin-27 on melanoma. Endocr Metab Immune Disord Drug Targets 10: 41-46, 2010.
13. Pang KR, Wu JJ, Huang DB, Tyring SK and Baron S: Biological and clinical basis for molecular studies of interferons. Methods Mol Med 116: 1-23, 2005.
14. Detjen KM, Farwig K, Welzel M, Wiedenmann B and Rosewicz S: Interferon-γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 49: 251-262, 2001. (Pubitemid 32675120)
15. Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, Tsokos M, Kontny HU and Mackall CL: Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 64: 8349-8356, 2004. (Pubitemid 39491774)
16. Rosevear HM, Lightfoot AJ, O'Donnell MA and Griffith TS: The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 28: 345-353, 2009.
17. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
18. Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo Martinez S, De Leon M, Langridge WH and Wall NR: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer 100: 1073-1086, 2009.
19. Murugaiyan G, Mittal A and Weiner HL: Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci USA 107: 11495-11500, 2010.
20. + T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat Immunol 12: 327-334, 2011.
21. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, Villarino AV, Huang Q, Yoshimura A, Sehy D, et al: Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 7: 937-945, 2006. (Pubitemid 44263907)
22. Shimozato O, Sato A, Kawamura K, Chiyo M, Ma G, Li Q and Tagawa M: The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses. Immunology 128: E816-E825, 2009.
23. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL and Eggermont AM: Synergistic antitumour effect of recombinant human tumor necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555, 1996. (Pubitemid 26120788)
24. Shen WH, Jackson ST, Broussard SR, Shen WH, Jackson ST, Broussard SR, McCusker RH, Strle K, Freund GG, Johnson RW, et al: IL-1β suppresses prolonged Akt activation and expression of E2F-1 and cyclin A in breast cancer cells. J Immunol 172: 7272-7281, 2004. (Pubitemid 38747586)
25. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
26. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
27. Yang D, Welm A and Bishop JM: Cell division and cell survival in the absence of surviving. Proc Natl Acad Sci USA 101: 15100-15105, 2004. (Pubitemid 39391725)
28. Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B and Lee SK: Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo. Cancer Lett 287: 196-206, 2010.
29. Banerjee S, Choi M, Aboukameel A, Wang Z, Mohammad M, Chen J, Yang D, Sarkar FH and Mohammad RM: Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas 39: 323-331, 2010.
30. Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, Huang DC and Adams JM: Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci USA 105: 18081-18087, 2008.